India Globalization Capital (NYSE: IGC) Shows Potential for Strong Market Valuation Growth
India Globalization Capital recently acquired exclusive patent rights for the use of low-dose THC as a potential therapeutic agent for Alzheimer’s disease No other publicly traded cannabis pharmaceutical company has a patent filing for a potential Alzheimer’s treatment Costs associated with Alzheimer’s disease top $236 billion in the U.S. and $600 billion globally India Globalization Capital, Inc. (NYSE MKT: IGC), a Maryland-based company, is currently preparing four products for medical trials, including Hyalolex for the treatment of Alzheimer’s disease. Alzheimer’s is a fatal, progressive brain disease that slowly destroys memory and thinking. Alzheimer’s is the leading cause of dementia and…







